Displaying drugs 5051 - 5075 of 10517 in total
Sevirumab
Investigational
SAR-439459
SAR-439459 is a pan-transforming Growth Factor-beta (TGFβ) neutralizing antibody. Developed by Sanofi, it is being investigated for the treatment of cancers and Osteogenesis Imperfecta.
Investigational
Matched Description: … [A259862] Developed by Sanofi, it is being investigated for the treatment of cancers and Osteogenesis …
SIS-101-ADO
SIS-101-ADO is a siRNA therapeutic under investigation for the treatment of Autosomal Dominant Osteopetrosis Type 2 (ADO2).
Investigational
Matched Description: … SIS-101-ADO is a siRNA therapeutic under investigation for the treatment of Autosomal Dominant Osteopetrosis …
SPG601
SPG601 is being investigated for the treatment of fragile X syndrome.
Investigational
Matched Description: … SPG601 is being investigated for the treatment of fragile X syndrome. …
Sovesudil
Investigational
Simufilam
Investigational
Saruparib
Saruparib is under investigation in clinical trial NCT06380751 (Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in Hr-positive, Her2-negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or Palb2m Advanced Breast Cancer).
Investigational
Phosphocreatine
Phosphocreatine - or creatine phosphate - is the phosphorylated form of creatine. It is primarily found endogenously in the skeletal muscles of vertebrates where it serves a critical role as a rapidly acting energy buffer for muscle cell actions like contractions via its ability to regenerate adenosine triphosphate (ATP) from...
Nutraceutical
Matched Description: … Phosphocreatine - or creatine phosphate - is the phosphorylated form of creatine. ... It is primarily found endogenously in the skeletal muscles of vertebrates where it serves a critical …
Avilamycin
Vet approved
Matched Iupac: … (2R,3S,4R,6S)-6-[(3aR,4R,4'R,5'S,6S,6'R,7aR)-6-{[(2S,3R,4R,5S,6R)-2-{[(2R,3S,4S,5S,6S)-6-[(2R,3aS,3'aR ... ,6'R,7R,7'S,7aR,7'aR)-7'-acetyl-6'-methyl-7-[(2-methylpropanoyl)oxy]-octahydro-2'H,3aH-2,4'-spirobi[[ …
(2s,4s)-Alpha-Campholinic Acid
Experimental
Selenomethionine Selenoxide
Experimental
(+)-menthol
Experimental
Barnidipine
Barnidipine is a long-acting novel calcium antagonist that belongs to the dihydropyridine (DHP) group of calcium channel blockers. Used in the treatment of hypertension, barnidipine displays high affinity for the calcium channels of the smooth muscle cells in the vascular wall and selectivity against cardiovascular L-type calcium channels . Barnidipine...
Experimental
Matched Description: … The active component is composed of a single optical isomer (*3'S, 4S* configuration), which is the most ... Used in the treatment of hypertension, barnidipine displays high affinity for the calcium channels of ... potent and longest-acting of the four enantiomers [A31567]. …
DYN-101
DYN-101 is an antisense product candidate designed to reduce the expression of dynamin 2 protein.
Investigational
Matched Description: … DYN-101 is an antisense product candidate designed to reduce the expression of dynamin 2 protein. …
SLV319
SLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid type 1 (CB1) receptor. It is developed for the treatment of obesity and other metabolic disorders.
Investigational
Matched Description: … It is developed for the treatment of obesity and other metabolic disorders. ... SLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid …
Sotirimod
Investigational
Sparteine
Sparteine is a plant alkaloid derived from Cytisus scoparius and Lupinus mutabilis which may chelate calcium and magnesium. It is a sodium channel blocker, so it falls in the category of class 1a antiarrhythmic agents. Sparteine is not currently FDA-approved for human use, and its salt, sparteine sulfate, is one...
Experimental
Withdrawn
Matched Description: … It is a sodium channel blocker, so it falls in the category of class 1a antiarrhythmic agents. ... Sparteine is not currently FDA-approved for human use, and its salt, sparteine sulfate, is one of the ... products that have been withdrawn or removed from the market for reasons of safety or effectiveness. …
Saralasin
Investigational
Sarcosine
Sarcosine has been investigated for the treatment of Schizophrenia.
Investigational
Matched Description: … Sarcosine has been investigated for the treatment of Schizophrenia. …
Sisomicin
Sisomicin has been used in trials studying the treatment of Pyoderma.
Investigational
Matched Description: … Sisomicin has been used in trials studying the treatment of Pyoderma. …
Sevuparin
Sevuparin is under investigation in clinical trial NCT03853421 (Placebo-controlled Study to Determine the Safety and Tolerability of Subcutaneous Doses of Sevuparin).
Investigational
Matched Description: … Subcutaneous Doses of Sevuparin). ... investigation in clinical trial NCT03853421 (Placebo-controlled Study to Determine the Safety and Tolerability of …
SEP-363856
SEP-363856 is a novel psychotropic drug being investigated for the treatment of schizophrenia. Unlike other drugs used for this condition, SEP-363856 does not bind to the dopamine D2 receptors, but exerts actions on the trace amine–associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5-HT1A). SEP-363856 was developed by Sunovion pharmaceuticals....
Investigational
Matched Description: … Additional clinical trials of SEP-363856 are required to confirm the safety and efficacy of this drug ... SEP-363856 is a novel psychotropic drug being investigated for the treatment of schizophrenia. ... initial clinical study has shown this drug may be effective against both positive and negative symptoms of …
Sarconeos
Sarconeos is an activator of the MAS receptor.
Investigational
Matched Description: … Sarconeos is an activator of the MAS receptor. …
Setanaxib
Investigational
Senaparib
Investigational
Displaying drugs 5051 - 5075 of 10517 in total